Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Has Average Price Target of $155.00

Key Points

• Analysts’ consensus is “Moderate Buy”: 13 of 16 analysts rate Abivax a buy, one a strong buy, one hold, and one sell. The average one-year price target is $155.
• ABVX opened at $87, below its 50-day average of $96.67 and 200-day average of $113.16; its 12-month trading range is $69.81–$148.83.
• Abivax reported quarterly EPS of -$1.71, missing the -$0.92 consensus estimate, while revenue of $1.37 million exceeded expectations of $0.80 million.

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $155.00.

Several equities analysts have recently issued reports on ABVX shares. Piper Sandler reiterated an "overweight" rating on shares of Abivax in a research report on Wednesday, October 21st. Guggenheim restated a "buy" rating and issued a $175.00 price objective on shares of Abivax in a report on Tuesday, October 20th. The Goldman Sachs Group started coverage on Abivax in a report on Wednesday, September 9th. They issued a "buy" rating and a $155.00 price objective for the company. Wedbush decreased their target price on Abivax from $118.00 to $96.00 and set a "neutral" rating for the company in a research note on Wednesday, October 21st. Finally, Truist Financial lowered their target price on Abivax from $155.00 to $151.00 and set a "buy" rating on the stock in a report on Tuesday, September 22nd.

Abivax Price Performance

Abivax stock opened at $87.00 on Tuesday. Abivax has a 12-month low of $69.81 and a 12-month high of $148.83. The stock has a market capitalization of $7.62 billion, a PE ratio of -14.36 and a beta of 1.36. The firm has a 50 day simple moving average of $96.67 and a 200-day simple moving average of $113.16.

Abivax (NASDAQ:ABVX - Get Free Report) last announced its earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to analysts' expectations of $0.80 million. On average, analysts forecast that Abivax will post -4.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

Several large investors have recently made changes to their positions in the business. Eversept Partners LP grew its stake in shares of Abivax by 42.0% in the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company's stock worth $104,048,000 after purchasing an additional 276,589 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Abivax by 31.6% during the first quarter. Janus Henderson Group PLC now owns 878,829 shares of the company's stock valued at $98,007,000 after purchasing an additional 211,068 shares during the last quarter. Bank of America Corp DE lifted its stake in Abivax by 40.9% during the first quarter. Bank of America Corp DE now owns 735,729 shares of the company's stock valued at $81,923,000 after purchasing an additional 213,440 shares during the last quarter. Aberdeen Group plc lifted its stake in Abivax by 45.8% during the third quarter. Aberdeen Group plc now owns 761,016 shares of the company's stock valued at $75,356,000 after purchasing an additional 238,991 shares during the last quarter. Finally, Two Seas Capital LP bought a new stake in Abivax during the third quarter worth approximately $66,996,000. Institutional investors own 47.91% of the company's stock.

About Abivax

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body's immune response.

The company's lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation.

Founded in 2013, Abivax conducts clinical development internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.